Investment Summary

HBM Partners AG Invests In Nuance Pharma

On December 7, 2020, private equity firm HBM Partners AG invested in life science company Nuance Pharma

Investment Highlights
  • This is HBM Partners AG’s 39th transaction in the Life Science sector.
  • This is HBM Partners AG’s 6th transaction in China.

Investment Summary
Date 2020-12-07
Target Nuance Pharma
Sector Life Science
Investor(s) HBM Partners AG
Deal Type Venture

Target

Nuance Pharma

Shanghai, China
Nuance Pharma is a specialty care focused biopharma with late late-stage clinical programs and existing commercial operations. Nuance Pharma was founded in 2014 and is based in Shanghai, China.

Search 200,291 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Investor(S) 1

Investor

HBM Partners AG

Investor Investor Investor Investor Investor

Category Private Equity Firm
Founded 2001
PE ASSETS 3.0B USD
Size Mega
Type Sector Focused
DESCRIPTION

HBM Partners is a private investment firm focused on investing in entrepreneurial biopharma and other healthcare-related companies in Europe, North America, India and other Emerging Markets. HBM looks to invest $5 to $50 million per transaction and will consider private and public companies. HBM Partners was established in 2001 and is headquartered in Zug, Switzerland.

DEAL STATS #
Overall 44 of 65
Sector (Life Science) 39 of 57
Type (Venture) 37 of 53
Country (China) 6 of 7
Year (2020) 16 of 17
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2020-11-24 Monte Rosa Therapeutics

Boston, Massachusetts, United States

Monte Rosa Therapeutics is a biotechnology company developing molecular glues to degrade disease-causing proteins. The company has developed a platform to rationally design small molecules that reprogram ubiquitin ligases to eliminate disease drivers previously deemed undruggable. The company’s drug discovery platform combines diverse and proprietary chemical libraries of small molecule protein degraders with in-house proteomics, structural biology, machine learning-based target selection, and computational chemistry capabilities to predict and obtain protein degradation profiles. Monte Rosa Therapeutics was founded in 2018 and is based in Boston, Massachusetts.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2020-12-16 Neuron23

South San Francisco, California, United States

Neuron23 is an early-stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological diseases. Neuron23 was founded in 2018 and is based in South San Francisco, California.

Buy -
Mergr

Product

Company

Legal